Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma

Gene Therapy

Volumn 22, Issue 9, 2015, Pages 707-720

  Sundarasetty, B S ^a   Chan, L ^b   Darling, D ^b   Giunti, G ^b   Farzaneh, F ^b   Schenck, F ^a   Naundorf, S ^c   Kuehlcke, K ^c   Ruggiero, E ^d   Schmidt, M ^d   Von Kalle, C ^d   Rothe, M ^e   Hoon, D S B ^f   Gerasch, L ^a   Figueiredo, C ^a   Koehl, U ^a   Blasczyk, R ^a   Gutzmer, R ^a   Stripecke, R ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c BIONTECH AG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e National Center for Tumor Diseases ^*  (Germany)

^f JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; LENTIVIRUS VECTOR; MELANOMA ANTIGEN; SMART DENDRITIC CELL TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG; CANCER VACCINE; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; PEPTIDE SVYDFFVWL;

ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CELL DIFFERENTIATION; CELL STIMULATION; CRYOPRESERVATION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG POTENCY; GOOD MANUFACTURING PRACTICE; HUMAN; IN VITRO STUDY; LENTIVIRINAE; MELANOMA; MONOCYTE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; DENDRITIC CELL; GENE VECTOR; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROCEDURES;

CANCER VACCINES; DENDRITIC CELLS; GENETIC VECTORS; HEK293 CELLS; HUMANS; IMMUNOTHERAPY; LENTIVIRUS; MELANOMA; MEMBRANE PROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84940899070     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.43     Document Type: Article

References (55)

1. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012; 12: 349-361.
2. Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer 2011; 47: 2150-2157.
3. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-365.
4. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-714.
5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
6. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8: e53745.
7. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
8. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R et al. Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumabrefractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109-1117.
9. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330.
10. Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunological reviews 2014; 257: 56-71.
11. Ott PA, Fritsch EF, Wu CJ, Dranoff G. Vaccines and melanoma. Hematol Oncol Clin North Am 2014; 28: 559-569.
12. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009; 58: 1-14.
13. De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003; 63: 12-17.
14. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Brocker EB et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006; 17: 563-570.
15. Lopez MN, Pereda C, Segal G, Munoz L, Aguilera R, Gonzalez FE et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumorspecific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol 2009; 27: 945-952.
16. Steele JC, Rao A, Marsden JR, Armstrong CJ, Berhane S, Billingham LJ et al. Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. Gene Ther 2011; 18: 584-593.
17. Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S et al. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother 2007; 56: 659-675.
18. Wilgenhof S, Van Nuffel AM, Benteyn D, Corthals J, Aerts C, Heirman C et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 2013; 24: 2686-2693.
19. Wilgenhof S, Corthals J, Van Nuffel AM, Benteyn D, Heirman C, Bonehill A et al. Long-term clinical outcome of melanoma patients treated with messenger RNAelectroporated dendritic cell therapy following complete resection of metastases. Cancer Immunol Immunother 2015; 64: 381-388.
20. Ribas A. Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther 2005; 5: 619-628.
21. Dullaers M, Breckpot K, Van Meirvenne S, Bonehill A, Tuyaerts S, Michiels A et al. Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. Mol Ther 2004; 10: 768-779.
22. Pincha M, Sundarasetty BS, Stripecke R. Lentiviral vectors for immunization: an inflammatory field. Expert Rev Vaccines 2010; 9: 309-321.
23. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen zreceptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.
24. Biffi A, Bartolomae CC, Cesana D, Cartier N, Aubourg P, Ranzani M et al. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 2011; 117: 5332-5339.
25. Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013; 341: 1233151.
26. Koya RC, Kimura T, Ribas A, Rozengurt N, Lawson GW, Faure-Kumar E et al. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Mol Ther 2007; 15: 971-980.
27. Pincha M, Sundarasetty BS, Salguero G, Gutzmer R, Garritsen H, Macke L et al. Identity, potency, in vivo viability, and scaling up production of lentiviral vectorinduced dendritic cells for melanoma immunotherapy. Hum Gene Ther Methods 2012; 23: 38-55.
28. Salguero G, Sundarasetty BS, Borchers S, Wedekind D, Eiz-Vesper B, Velaga S et al. Preconditioning therapy with lentiviral vector-programmed dendritic cells accelerates the homeostatic expansion of antigen-reactive human T cells in NOD. Rag1(- / -).IL-2rgammac(- / -) mice. Hum Gene Ther 2011; 22: 1209-1224.
29. Pincha M, Salguero G, Wedekind D, Sundarasetty BS, Lin A, Kasahara N et al. Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells. Gene Ther 2011; 18: 750-764.
30. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184: 2207-2216.
31. Schmidt M, Schwarzwaelder K, Bartholomae C, Zaoui K, Ball C, Pilz I et al. Highresolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR). Nat Methods 2007; 4: 1051-1057.
32. Cattoglio C, Facchini G, Sartori D, Antonelli A, Miccio A, Cassani B et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 2007; 110: 1770-1778.
33. Pak BJ, Lee J, Thai BL, Fuchs SY, Shaked Y, Ronai Z et al. Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase. Oncogene 2004; 23: 30-38.
34. Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol 2006; 126: 2658-2663.
35. Khong HT, Rosenberg SA. Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J Immunol 2002; 168: 951-956.
36. Paschen A, Song M, Osen W, Nguyen XD, Mueller-Berghaus J, Fink D et al. Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1∗0301 transgenic mice. Clin Cancer Res 2005; 11: 5241-5247.
37. Umansky V, Abschuetz O, Osen W, Ramacher M, Zhao F, Kato M et al. Melanomaspecific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res 2008; 68: 9451-9458.
38. Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M et al. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 2010; 120: 2030-2039.
39. Kuo CT, Hoon DS, Takeuchi H, Turner R, Wang HJ, Morton DL et al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffinembedded sentinel lymph nodes. J Clin Oncol 2003; 21: 3566-3572.
40. Takeuchi H, Kuo C, Morton DL, Wang HJ, Hoon DS. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res 2003; 63: 441-448.
41. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571.
42. Linnemann C, van Buuren MM, Bies L, Verdegaal EM, Schotte R, Calis JJ et al. Highthroughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med 2015; 21: 81-85.
43. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013; 341: 1233158.
44. Merten OW, Charrier S, Laroudie N, Fauchille S, Dugue C, Jenny C et al. Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 2011; 22: 343-356.
45. Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A et al. Dendritic cellbased vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep 2012; 28: 1131-1138.
46. Ellebaek E, Engell-Noerregaard L, Iversen TZ, Froesig TM, Munir S, Hadrup SR et al. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother 2012; 61: 1791-1804.
47. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509-1518.
48. Daenthanasanmak A, Salguero G, Borchers S, Figueiredo C, Jacobs R, Sundarasetty BS et al. Integrase-defective lentiviral vectors encoding cytokines induce differentiation of human dendritic cells and stimulate multivalent immune responses in vitro and in vivo. Vaccine 2012; 30: 5118-5131.
49. Salguero G, Daenthanasanmak A, Munz C, Raykova A, Guzman CA, Riese P et al. Dendritic cell-mediated immune humanization of mice: implications for allogeneic and xenogeneic stem cell transplantation. J Immunol 2014; 192: 4636-4647.
50. Yanez-Munoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 2006; 12: 348-353.
51. Rothe M, Rittelmeyer I, Iken M, Rudrich U, Schambach A, Glage S et al. Epidermal growth factor improves lentivirus vector gene transfer into primary mouse hepatocytes. Gene Ther 2012; 19: 425-434.
52. Sarantou T, Chi DD, Garrison DA, Conrad AJ, Schmid P, Morton DL et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer research 1997; 57: 1371-1376.
53. Sundarasetty BS, Singh VK, Salguero G, Geffers R, Rickmann M, Macke L et al. Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia. Hum Gene Ther 2013; 24: 220-237.
54. Badralmaa Y, Natarajan V. Impact of the DNA extraction method on 2-LTR DNA circle recovery from HIV-1 infected cells. J Virol Methods 2013; 193: 184-189.
55. Daenthanasanmak A, Salguero G, Sundarasetty BS, Waskow C, Cosgun KN, Guzman C A et al. Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMV. Mol Ther Methods Clin Dev 2014; 1: 14060.